Literature DB >> 19269709

Funding and access to high cost medicines in public hospitals in Australia: decision-makers' perspectives.

Gisselle Gallego1, Susan Joyce Taylor, Jo-Anne Elizabeth Brien.   

Abstract

AIM: To investigate the perceptions, concerns and attitudes of decision-makers regarding access to high cost medicines (HCMs) in public hospitals.
METHODS: In-depth semi-structured interviews were conducted with 24 decisions-makers (executive directors of hospitals, area health service managers, directors of hospital pharmacy departments and senior medical doctors) in a Sydney Area Health Service. The interviews were digitally recorded and transcribed and analysed using a modified grounded theory approach.
RESULTS: Decision-makers perceived health care system funding models as obstacles to equity of access to HCMs. They were concerned that there were inequities in decisions for individual patients according to public or private sector status. A major concern for respondents was the lack of consistency in decision-making about funding for HCMs. Respondents described that besides safety, efficacy, effectiveness and cost, ethical principles should be borne in mind when deciding whether a HCM should be available in a public hospital. Most wanted a consistent, transparent, accountable, evidence-based decision-making process.
CONCLUSIONS: The results of this study suggest that decision-makers were concerned about the equity of access to HCMs in public hospitals and wanted an explicit, systematic process to allocate resources to HCMs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19269709     DOI: 10.1016/j.healthpol.2009.02.001

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  5 in total

1.  Hospital drug and therapeutics committees in Australia: is there a role for economic evaluation at the institutional level?

Authors:  Gisselle Gallego
Journal:  Int J Clin Pharm       Date:  2011-12

Review 2.  Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.

Authors:  Tatjana E MacLeod; Anthony H Harris; Ajay Mahal
Journal:  Patient       Date:  2016-06       Impact factor: 3.883

Review 3.  HOSPITAL MANAGERS' NEED FOR INFORMATION ON HEALTH TECHNOLOGY INVESTMENTS.

Authors:  Anne Mette Ølholm; Kristian Kidholm; Mette Birk-Olsen; Janne Buck Christensen
Journal:  Int J Technol Assess Health Care       Date:  2016-02-15       Impact factor: 2.188

4.  'You can give them wings to fly': a qualitative study on values-based leadership in health care.

Authors:  Yvonne Denier; Lieve Dhaene; Chris Gastmans
Journal:  BMC Med Ethics       Date:  2019-05-27       Impact factor: 2.652

5.  Identifying priority medicines policy issues for New Zealand: a general inductive study.

Authors:  Zaheer-Ud-Din Babar; Susan Francis
Journal:  BMJ Open       Date:  2014-05-28       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.